Building An In-House Cell & Gene Manufacturing Facility: Best Practices & Lessons Learned

The recent market downturn has most certainly impacted cell and gene therapy's build versus buy debate. Yet, with flexible and sustainable design strategies and best practices and contingency planning based on current market conditions and exit strategies, building an in-house facility is feasible.

Cell & Gene Live's Erin Harris hosted a panel of subject matter experts who shared their experiences in building state-of-the-art manufacturing facilities and offered detailed advice on how your company may do the same. Available on-demand thanks to the support of Entegris.